key: cord-0893598-dxki764x authors: Gökmen, Refik; Cronin, Antonia; Brown, Wendy; Cass, Stephen; Ghazanfar, Abbas; Hossain, Mohammad Ayaz; Johnson, Jenny; Longdon, Trish; Lyon, Sue; McLean, Adam; Motallebzadeh, Reza; Popoola, Joyce; Samuel, Ayo; Thuraisingham, Raj; Wood, Angela‐Jane; Dor, Frank JMF title: Kidney transplantation and patients who decline SARS‐CoV‐2 vaccination: an ethical framework date: 2021-07-19 journal: Transpl Int DOI: 10.1111/tri.13979 sha: 0f81ac5c1a26ac55d8a5f09ab8904890bdaa82b6 doc_id: 893598 cord_uid: dxki764x The COVID‐19 pandemic has had a major impact on kidney transplantation and on patients with end‐stage kidney disease. Transplantation activity has been substantially reduced, and kidney transplant recipients have suffered increased mortality. The introduction of vaccines against SARS‐CoV‐2 has offered considerable hope that it may be possible to protect patients from the risks associated with SARS‐CoV‐2 infection, and that more patients may once again have access to kidney transplantation. The COVID-19 pandemic has had a major impact on kidney transplantation and on patients with endstage kidney disease. Transplantation activity has been substantially reduced, and kidney transplant recipients have suffered increased mortality. The introduction of vaccines against SARS-CoV-2 has offered considerable hope that it may be possible to protect patients from the risks associated with SARS-CoV-2 infection, and that more patients may once again have access to kidney transplantation. However, as the SARS-CoV-2 vaccines have started to be rolled out, it has become clear that a significant proportion of the population has been hesitant about being vaccinated, and uptake of the vaccines in potential kidney transplant recipients has not been universal. Although data from the UK Household Longitudinal study showed overall high levels of willingness (82%) to take up the SARS-CoV-2 vaccine, high levels of vaccine hesitancy were noted in certain groups [1] . Similar variations in intention to be vaccinated have been shown in the USA [2] , Italy [3] , and other national surveys [4] . Unpublished data from one centre in London shows that between 3.5 to 18.6% of patients undergoing satellite haemodialysis have declined vaccination to date. In this context, one of the key questions facing transplant units has been whether listing for transplantation should be contingent on potential transplant recipients having received the vaccine. This article is protected by copyright. All rights reserved In order to provide more detailed practical guidance for transplant units for this group of patients, the Pan London Transplant Collaborative (PLTC) convened a Collaborative Ethics Group comprising lay members, patients and transplant professionals, many of whom had a special interest in medical ethics. Group membership was selected to reflect the diversity of the local population, and patient representatives included both kidney transplant recipients and patients on the kidney transplant waiting list. The group's co-chairs undertook a literature review, which was followed by a moderated group discussion focusing on describing and evaluating ethical arguments for and against mandating vaccination. The co-chairs also took the issue to the clinical ethics committees at Guy's and St Thomas' NHS Foundation Trust and Imperial College Healthcare NHS Trust, each with similarly broad membership comprising professionals and lay members, but with expertise outside the field of transplantation. The perspectives of the clinical ethics committees were fed back to the PLTC Collaborative Ethics Group; a summary guidance document was prepared by the co-chairs and presented to the group for consensus. A summary of this guidance has been provided to UK transplant centres [6]; this review aims to broaden the scope of this guidance for transplant units internationally. the deceased donor transplant waiting list: 1.1.1. There is concern that the risks associated with kidney transplantation without prior vaccination against COVID-19 may be excessive. Data from our own cohorts in London has shown that although COVID-19 infections were more common in waitlisted patients, COVID-19 associated mortality is higher in transplant recipients (hazard ratio 3.36) [7] ; this has also been demonstrated in a national UK registry-based cohort analysis [8] . A similar increase in the risk of more severe disease in kidney transplant recipients as compared with haemodialysis patients has been reported in both retrospective and prospective analysis of European registry data [9, 10] . There is further concern that SARS-CoV-2 infection in the immediate post-transplant period is likely to bring significant additional risk of mortality [10] . This risk can be compounded by other COVID-associated risk factors, including age, diabetes and obesity [11] [12] [13] . 1.1.2. The desire to protect patients against excessive risks has underpinned the decision to defer reactivation on the deceased donor transplant waiting list for many patients during the pandemic in risk stratified groups, and therefore represents a consistency of approach. However, to date there are no published empirical data allowing assessment of this cautious approach. 1.2.1. It may be argued that admitting unvaccinated patients onto transplant wards may put other patients and staff at risk, and potentially affect the hospital as a whole. While clinicians will need to act in the best interests of individual patients, they will also need to ensure the safety of others. This article is protected by copyright. All rights reserved principles of transplantation ethics is to maximise the benefit derived from the scarce resource of donated organs; there is legitimate concern that kidneys may be expected to have better outcomes when transplanted into vaccinated recipients as compared with recipients who have declined vaccination. This article is protected by copyright. All rights reserved 2.1.1. Mandating a particular treatment overrides the fundamental principle of autonomy. Healthcare professionals are well-accustomed to respecting patient decisions which may be associated with increased risk, and with which they themselves might disagree. 2.1.2. Public Health England and the UK Government have not issued specific guidance on consent to SARS-CoV-2 vaccination, and whether there may be any basis for mandated vaccination. By comparison, The Council of Europe has urged EU member states to ensure that citizens are informed that vaccination is not mandatory, and that no one is discriminated against for not having been vaccinated [14]. 2.2.1. It has become clear that vaccine hesitancy is common in particular patient groups [1, 15] . This includes but is not restricted to minority ethnic populations, who already have reduced access to transplantation, and have been particularly impacted by the COVID-19 pandemic, especially in London. In this context, there is significant concern that mandating vaccination prior to transplant listing would cause more damage to trust in the medical profession, and further exacerbate health inequalities [16] . Irrespective of any theoretical reasons for considering vaccination to be a valid prerequisite for transplant listing, this potentially harmful practical impact on equity of access and trust within disadvantaged communities has emerged as a key objection to any such approach. There may be number of potential uncertainties associated with a policy of mandating vaccination, some of which might render such an approach unworkable. These include: To what extent can we protect each and every patient with the vaccine? The efficacy of This article is protected by copyright. All rights reserved diminished as compared with the general population [17] [18] [19] [20] [21] 2.3.7. If it has been determined that it may be in the best interests of a patient that lacks capacity to be listed for deceased or living donor transplantation, would that imply that vaccination should also be undertaken, in the potential recipient's best interests? Many of the same arguments as stated above for deceased donor kidney transplantation would also apply to directed living donor transplantation, with the key exception of any consideration given to optimal utilisation of a scarce public resource. If a recipient declines the opportunity to be vaccinated prior to receiving a living donor kidney transplant, both recipient and donor will need to consider the increased risks to recipient and graft survival associated with this. The transplant team may feel that the transplant may proceed if donor and recipient have both given informed consent taking into account these additional risks: this may be analogous to situations where recipients have a high risk of graft loss due to recurrent primary disease but donors nevertheless consent to donation. 4.1. As set out above, cogent arguments can be made both for and against mandating vaccination prior to listing for deceased or living donor kidney transplantation. However, This article is protected by copyright. All rights reserved fundamental concerns regarding equity of access, public trust and practical uncertainties have led many in the transplant community to conclude that a blanket policy of mandating vaccination prior to listing for deceased or living donor kidney transplantation would not be ethically desirable, would be unworkable, and may do more harm than good. It would go against the principle of autonomy and patient choice, and may deprive potential recipients of the benefits of transplantation. 4.2. Nevertheless, these concerns must be reconciled with our duty to protect patients from harm and to act as responsible stewards of the scarce resource of donor organs. 4.3.6. When making these risk assessments, it is unlikely that unvaccinated patients will be included in the first phase of cautious reopening of transplant programmes, when it will be important to ensure that risk is minimised as far as possible. However, conversations with patients should centre on an overall assessment of risk, and strong encouragement to take up opportunities for vaccination. This article is protected by copyright. All rights reserved Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study COVID-19 Vaccination Hesitancy in the United States: A Rapid National Assessment Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy Accepted Article This article is protected by copyright. All rights reserved International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples Informing the risk of kidney transplantation versus remaining on the waitlist in the Coronavirus Disease 2019 era SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: A national cohort study Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe COVID-19 related mortality in kidney transplant and hemodialysis patients: a comparative, prospective registry based study Identification of patient characteristics associated with SARS-CoV-2 infection and outcome in kidney transplant patients using serological screening Mortality rates in transplant recipients and transplantation candidates in a high-prevalence COVID-19 environment COVID-19 in solid organ transplant: A multi-center cohort study Kidney Transplant Recipient Attitudes Toward a SARS-CoV-2 Vaccine High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients